Hospital Quirón, Department of Allergology, Barcelona, Catalonia, Spain.
Expert Opin Drug Saf. 2013 May;12(3):445-53. doi: 10.1517/14740338.2013.788148. Epub 2013 Apr 11.
Desloratadine is a biologically active metabolite of second-generation antihistamine loratadine. It is also indicated for the treatment of allergic diseases, including allergic rhinitis.
A Medline search was conducted to identify preclinical and clinical studies of desloratadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of desloratadine.
The review of these data indicates that the safety profile of desloratadine is similar to other second-generation antihistamines. Desloratadine is highly selective for histamine H₁-receptors, does not cross the blood-brain barrier (BBB), and has minimal adverse events (very low sedation rate), with a better safety and tolerability than first-generation antihistamines. Desloratadine is safe and well tolerated without having central nervous system (CNS) or cardiovascular effects and with low drug interaction.
地氯雷他定是第二代抗组胺药氯雷他定的生物活性代谢物。它也被用于治疗过敏疾病,包括过敏性鼻炎。
进行了 Medline 搜索以确定地氯雷他定的临床前和临床研究。此外,还从在线资源中获得了其他文章。这篇综述的重点是地氯雷他定的安全性概况。
对这些数据的回顾表明,地氯雷他定的安全性概况与其他第二代抗组胺药相似。地氯雷他定对组胺 H₁受体具有高度选择性,不会穿过血脑屏障 (BBB),并且不良事件(非常低的镇静率)很少,安全性和耐受性优于第一代抗组胺药。地氯雷他定安全且耐受良好,没有中枢神经系统 (CNS) 或心血管作用,药物相互作用低。